Devices and methods for delivery of pharmaceutical compositions

1. A method for a user to deliver a naloxone containing formulation to a nasal mucosa of an individual having an opioid overdose, the method comprising:

(a) receiving, by the user, a delivery device, wherein the delivery device comprises:

a nasal applicator, wherein the nasal application comprises a shaft an application tip coupled to the shaft;

an absorbent material coupled to the applicator tip; and

a naloxone-containing formulation retained by the absorbent material, wherein the naloxone-containing formulation has a naloxone concentration of at least 45 mg/mL;

(b) inserting, by the user, the applicator tip into the nasal passage of the individual a single time; and

(c) contacting, by the user, the absorbent material to a portion of the nasal mucosa between from 1.5 cm to 3.0 cm from an opening of the nasal passage;

wherein from 0.1 mg to 20 mg of naloxone HCl is delivered to the nasal mucosa without the applicator penetrating the surface of the nasal mucosa, and

following the delivery of naloxone HCl to the nasal mucosa, the pharmacokinetics of the plasma naloxone HCl concentration is characterized by a measured T max that is at least 20% less than the T max administered using the same dose of naloxone via a nasal spray;

to thereby treat the opioid overdose.

2. The method of claim 1 , wherein the absorbent material comprises a swab.

3. The method of claim 1 , wherein the naloxone containing formulation has a pH from 3.5 to 5.5.

4. The method of claim 1 , wherein the naloxone containing formulation is an aqueous formulation.

5. The method of claim 1 , wherein the absorbent material comprises at least 150 μL of the naloxone containing formulation.

6. The method of claim 1 , wherein a total dosage of naloxone HCl that is delivered to the nasal mucosa is from 4 milligrams to 20 milligrams.

7. The method of claim 1 , wherein the naloxone-containing formulation has a naloxone HCl concentration from 45 mg/mL to 90 mg/mL.

8. The method of claim 1 , wherein the absorbent material contains a pre-metered dose of naloxone HCl.

9. The method of claim 1 , wherein the naloxone-containing formulation comprises a stabilizing agent, a tonicity agent, a chelating agent, and a preservative.

10. The method of claim 1 , wherein the naloxone-containing formulation comprises water, naloxone HCl, citric acid, ethylenediaminetetraacetic acid, benzalkonium chloride, and sodium chloride.

11. The method of claim 1 , wherein the naloxone-containing formulation consists of water, naloxone HCl, citric acid, ethylenediamine tetra acetic acid, benzalkonium chloride, and sodium chloride.

12. The method of claim 1 , wherein from 20 μL to 300 μL of the naloxone-containing formulation is delivered to the nasal mucosa.

13. A method of treating an opioid overdose in an individual in need of such treatment, comprising:

(a) inserting a nasal applicator into a nasal passage of the individual, wherein, the nasal applicator comprises a tip comprising an absorbent material;

the absorbent material comprises a pre-metered dose of an aqueous naloxone-containing formulation; and

the naloxone-containing formulation comprises:

a naloxone HCl concentration from 45 mg/mL to 90 mg/mL;

water, naloxone HCl, citric acid, ethylenediamine tetraacetic acid, benzalkonium chloride, and sodium chloride;

a viscosity from 0.1 centipoise to 10 centipoise at 20° C.; and

a pH from 3.5 to 5.5; and

(b) contacting a portion of the nasal mucosa between from 1.5 cm to 3.0 cm from an opening of the nasal passage to deliver a therapeutically effective amount of naloxone HCl to the systemic circulation of the patient for treating the opioid overdose;

(c) wherein the pharmacokinetics of the plasma naloxone HCl concentration is characterized by a measured T max that is at least 20% less than the T max administered using the same dose of naloxone HCl via a nasal spray.

14. The method of claim 13 , wherein delivering comprises delivering from 20 μL to 300 μL of the naloxone-containing formulation to the nasal mucosa.

15. The method of claim 13 , wherein from 0.1 mg to 20 mg of naloxone HCl is delivered to the nasal mucosa.